Neurona's neural cell therapies have single-dose curative potential. Based on a novel neural cell lineage pioneered by the company's scientific founders, Neurona has built a robust regenerative platform and is developing neuronal, glial, and gene-edited cell therapy candidates that provide long-term repair of dysfunctional neural networks for multiple neurological disorders.

Key Contact

Funding Events

Date	Amount	Type	Investors	Valuation
06/22/21	$41,500,000	Venture	Alexandria Venture Investments Ironfire Ventures Sphera Funds Management The Column Group UCB Ventures	undisclosed
02/08/24	$120,000,000	Venture	Alexandria Venture Investments Berkeley Frontier Fund Cormorant Asset Management Euclidean Capital LYFE Capital Schroders Capital Sphera Funds Management Spur Capital Partners Symbiosis The Column Group UC Investments UCB Ventures Viking Global Investors Willett Advisors Ysios Capital	undisclosed